New hope for rare cholesterol disease: can evinacumab shrink dangerous plaque?
NCT ID NCT07447648
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows about 52 people with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol and early heart disease. Researchers will compare those who get evinacumab (a cholesterol-lowering antibody) added to their usual treatment against those on standard therapy alone. Using CT scans of the heart, they will measure changes in artery plaque over 18-24 months to see if evinacumab helps stabilize or reduce plaque buildup.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- evinacumab (a lab-made antibody that lowers cholesterol by blocking a protein called ANGPTL3)
- What this could lead to
- If successful, this study could show that adding evinacumab to standard treatment helps slow or shrink dangerous artery plaque in people with HoFH, pointing toward better long-term heart health.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It is also small (52 people) and early-stage, so findings may not apply to everyone or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Amsterdam University Medical Center, Amsterdam UMC, locatie AMC
RECRUITINGAmsterdam, Netherlands
-
Centro per le Malattie Rare del Metabolismo dei Lipidi, Unità di Medicina Interna e Malattie Metaboliche, Dipartimento di Medicina Traslazionale e di Precisione Sapienza, Università di Roma
RECRUITINGRoma, Italy
-
DAI di Medicina Clinica, Centro di Riferimento Regionale di Lipidologia e Dislipidemie, AOU Federico II di Napoli
RECRUITINGNaples, Italy
-
Dipartimento Scienze-Cardiovascolari, AO "Sant'Anna e San Sebastiano" di Caserta
RECRUITINGCaserta, Italy
-
Ege University,Director of Lipid and Prevention Clinic, Department of Cardiology
RECRUITINGBornova, Turkey (Türkiye)
-
Erasmus University Medical Center, Dr. Molewaterplein 40
NOT_YET_RECRUITINGRotterdam, Netherlands
-
Malattie Aterotrombotiche, Azienda Ospedaliero Universitaria Careggi
RECRUITINGFlorence, Italy
-
Medicina Interna, Ospedale Molinette, AOU Città della Salute e della Scienza
NOT_YET_RECRUITINGTorino, Italy
-
Nefrologia e Emodialisi, Centro Aterosclerosi e Dislipidemie, Ospedale Bassini, ASST Nord Milano
RECRUITINGCinisello Balsamo, Italy
-
U.O. Astanteria/MCAU AOU, Policlinico "Paolo Giaccone" di Palermo
RECRUITINGPalermo, Italy
-
U.O.C. di Medicina Interna, P.O. Nesima, ARNAS Garibaldi
NOT_YET_RECRUITINGCatania, Italy
-
UOC Clinica Medica I, AOU di Padova
NOT_YET_RECRUITINGPadova, Italy
-
Unité de Lipidologie et Prévention Cardiovasculaire, Centre de Compétence Dyslipidémies Rares (CEDRA), Service de Nutrition, Hôpital Pitié-Salpétriêre
NOT_YET_RECRUITINGParis, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could spot hidden heart attack risks before It's too late
- CT-Guided heart stenting could cut procedure time and radiation
- New drug aims to slash Sky-High cholesterol in rare genetic disease
- New drug shows promise for rare high cholesterol condition
- CRISPR therapy takes aim at stubborn high cholesterol in first human trial
- New study screens newborns for inherited high cholesterol